Efficacy Study of FANG(30) for Active Rheumatoid Arthritis in Adult Patients
Efficacy Study of FANG(30) for Active Rheumatoid Arthritis in Adult Patients
This is a Clinical Pilot Phase II interventional, double blind, randomized and placebo
 controlled study to document the efficacy, tolerability and safety of FANG(30) in 60 adult
 patients affected with active Rheumatoid Arthritis. Also, to evaluate the effect of an
 andrographolide natural formula, identified as FANG(30) or "the study product", on the
 immunological functions that influence chronic inflammatory process in these patients, who
 could benefit with this treatment.
Introduction: Rheumatoid Arthritis (RA) is a common rheumatic disease characterized by pain,
 inflammation and reduction in joint function. Hands and feet are the most commonly affected
 joints and pain is the cause that brings patients with RA to search for medical assistance.
 Factors causing pain and the risk of physical incapacity are still poorly understood. Joint
 pain in RA is, generally, a profound pain, focalized in the involved joint. Typically, pain
 increases when joint moves and decreases when joint is at rest. But, in the advanced form of
 the disease, pain can be persistent and some patients can feel night pain, or rigidity and
 pain after a period of inactivity, that last more than 1 hour and decreases when some
 activity is taken up again, i.e. rigidity and early morning pain. Clinically, these patients
 present with symptoms such as localized sensibility on the joints, and slight edema of the
 tissue, bone crepitating and heat on the outer joint. Muscular atrophy with or without
 muscular spasm can be seen. In the advanced form of the disease, there is deformity and
 complete loss of joint movement. Analgesic drugs, specially the non steroidal
 anti-inflammatory drugs NSAIDs play an essential role in the management of RA. These drugs
 are not only effective in the rapid and sustained relief of pain, but at the same time they
 can have an acceptable profile of safety and tolerability in medium and long term treatment.
 However, there are cases of gastric intolerance and /or renal or hepatic dysfunction. The
 anti-inflammatory effect of non steroidal anti-inflammatory drugs NSAIDs, is mainly due to
 the inhibition of the cyclooxygenase enzyme (COX), that is needed for the synthesis of
 prostaglandins and thromboxanes.

 Description of FANG used in this clinical trial: FANG(30) is a product manufactured by
 FARMINDUSTRIA S.A., Pharmaceutical Laboratories, Santiago, Chile, in the form of a common
 medicine, according to Good Manufacturing Practices (GMP) Guidelines & Requirements of the
 Institute of Public Health of Chile (ISP), from a standardized and patented extract of A.
 paniculata, Nees (Acanthaceae), a medicinal plant native to India and China. Its chemical
 composition and principal active compounds are bitter diterpenic lactones, specially
 andrographolide, deoxy-andrographolide and neoandrographolide, in tablets weighting 100 mg
 with a 30 % of the active principle. This plant is vastly distributed in the countries of
 Southeast Asia and has been used as an official medicinal plant in China and India for
 thousands of years. It still continues as a popular medicine for the treatment of different
 diseases. Recently it has been demonstrated to possess anti tumoral5, anti-inflammatory6 and
 antiviral7 effects. Andrographolide is particularly efficient in regulating the immune
 response 5, 7. The molecular and cellular mechanisms responsible for the immunomodulating and
 anti-inflammatory properties of andrographolide, remain still unknown, however, recent in
 vitro and in vivo studies, indicate that andrographolide inhibits NFkappaB8. Specifically,
 andrographolide in concentrations of 10 µM interferes with the DNA binding of NF-κB reducing
 the expression of COX-2 in neutrophils induced with fMLP and PAF. Moreover, andrographolide
 reduces the production of IFNγ and IL-2 in T cells stimulated with CON-A, without affecting
 the cellular viability or inducing apoptosis. Also the apoptosis induced by corticosteroids
 in thymocytes was reduced. Andrographolide and 14-deoxyandrographolide are able to inhibit
 the ERK1/2 phosphorylation in T cells and neutrophils, respectively 9, 10. In inflammatory
 processes, FANG has shown potent anti-inflammatory effects, reducing the production of
 cytokines, derived from phospholipids, nitric oxide and reactive oxygen species that are the
 "fuel" for chronic inflammation, explaining its capacity to reduce and control inflammation,
 inflammatory pain and facilitate the induction of cellular repair. Clinical Evidence of some
 effects of A. paniculata: During the last decades, A. paniculata has become popular in
 Scandinavia for the treatment of common cold. Accumulated evidence indicates that it can
 reduce the severity of this disease. Various clinical studies indicate that A. paniculata is
 effective for the treatment of viral infections of the upper respiratory tract. A
 meta-analysis in 2004 on 7 double blind controlled clinical trials that met the criteria and
 scientific quality accepted for this meta design, including 896 participants, which evaluated
 the efficacy of A. paniculata for the treatment of acute respiratory infections11, indicates
 in the combined results, that A. paniculata was more effective than the placebo in reducing
 the symptoms of common cold. A. paniculata has also been compared to acetaminophen. In a
 double blind randomized study with 152 patients with fever and pharyngeal congestion 12 high
 doses of A. paniculata (6 g) reduced fever and sore throat in a similar manner to
 acetaminophen, without significant secondary effects. In a double blind randomized trial,
 against a placebo, with 107 patients, A. paniculata increased resistance to common cold 13,
 reducing the incidence of colds by a factor of 2.1 times compared to the control group after
 a 3 months treatment during winter season. Safety Parameters - Toxicity and Tolerability of
 FANG: Acute and sub-chronic toxicity in rodents and pigs using an extract of A. paniculata
 the component of FANG, performed at the Institute of Pharmacology and Toxicology, Universidad
 Austral de Chile according to Good Laboratory Practice (GLP) and Food Administration Agency
 (FDA), showed the absence of adverse effects with doses >20g/kg after 90 days of treatment.
 Not genetic, or reproductive, immunological, neurological, hematological, metabolic,
 histopathological toxicity were detected either. Also, in a Phase I clinical trial, where the
 participants were monitored for liver, renal and hematological parameters, no clinical or
 laboratory secondary effects were described 11, 13, 15. Bio safety studies in small children,
 nursing mothers, patients with renal or hepatic damage have not been performed yet. On the
 other hand, since A. paniculata can stimulate the contractibility of gall bladder. Therefore,
 it should not be used without medical supervision or in patients with gall bladder pathology.

 Objective of Study: To assess and measure the anti inflammatory efficacy of this test natural
 product and contribute learning about some of the basic biological mechanisms by which
 produces its effects, on adult patients with active Rheumatoid Arthritis. Methodology: For
 this purpose, there will be 2 groups of patients who will respectively receive at random, an
 either inert substance known as placebo, and the other group that will receive the test
 product in the form of coated tablets, three times every day, during the period of study that
 will last 14 weeks.

 Place of Study: National study in Chile with 2 centers, one in the city of Valdivia and one
 in the city of Osorno with a number of 30 patients per centre and enrolled by their
 respective rheumatologists. Population of Study: 60 adult individuals of both sexes diagnosed
 with Active Rheumatoid Arthritis and undergoing standard treatment will be included.
 Individuals with chronic or acute disease, smokers, alcoholics, diabetics, heart diseases,
 lung diseases, neoplastic diseases, and individuals taken any other medicine will be
 excluded. Product of Study: The experimental FANG (30) and the placebo tablets were
 manufactured and stored as specified, and will be delivered and administered as proposed in
 this protocol. Procedure: A total of approximately 30 individuals will be assigned to the
 placebo group, and 30 to the FANG(30) group. During 14 weeks, each of them will daily take 3
 tablets of the respective randomly assigned product. All volunteers will allow obtaining a
 monthly blood sample by simple venipuncture from the superior arm at day 0, 30, 60, 90 and
 120 days of treatment.

 Discomfort and derived risks of the study: Since the participants, will need to take tablets
 of the product 3 times a day and submitted to the extraction of 4 blood samples during the
 study period, these facts can represent in some cases, a physical and emotional discomfort,
 depending of the customs and individual predisposition for this type of common medical
 procedures. Adverse Effects: Andrographis paniculata extract is not toxic and the
 manufactured product FANG(30) is prepared under GMP with pharmaceutical quality as requested
 for this study. The product is well tolerated and no complications are reported in the vast
 available information. However, as any natural and / or pharmaceutical product, in isolated
 cases, there can be slight risks such as rushes, allergies to the active principles of the
 plant, which anyhow, are reversible with the suspension of the intake of the product.
 Moreover, if in one of the patients, an alteration is detected that could be dangerous or
 inconvenient for his or her health condition; physicians will offer this patient to withdraw
 from the study. In case of a severe alteration, the rheumatologist will withdraw the patient
 from the study for safety reasons.

 Principal expected results: At the end of the study period, participants receiving the active
 product FANG (30) (Andrographis extract tablets), should show an improvement in their
 symptoms. Moreover, participants that received placebo should not show any sign of change in
 their symptoms. Any situation of health detected during the course of the study, related to
 the analyzed parameters, or any other aspects of clinical significance, even not necessarily
 included in this study, will be duly recorded and informed accordingly. If end results
 demonstrate that FANG(30) in a particular case has proven to be beneficial, all participating
 patients (even those having received a placebo) will be offered by their rheumatologists a
 free treatment with this same medicine in a regular modality, for the next 18 months.

 Volunteering: Volunteers must be absolutely free to apply and participate, in order to be
 included in this study, as for no reason whatsoever nobody can oblige a person to participate
 under any condition or threat. Moreover, volunteers can abandon and not continue
 participating in this study at any moment and without necessity of given explanations. This
 event will not affect the relationships with treating physicians, neither with the personnel
 of the hospital, or have any relation or influence with volunteer's future health care
 requirements. Volunteers can, and must consult all doubts about the study in which they have
 been invited to participate, before accepting and also during development of the study.
 Insurance for the Study: Considering the previous experience with the drug, of being of free
 sale in other countries; being approved by the Institute of Public Health in Chile,
 authorized to be sold as a nutraceutical in the USA, no hiring of specific insurance for
 special risks of this study has been considered. Moreover, this study has no special funds
 for the payment of compensations for damages resulting from adverse effects to the test
 medicine. Nevertheless, in case some event of this nature would happen, volunteers will be
 assisted with all the procedures and therapies they require, and continue to be monitored by
 a study physician for their care. In case of additional interventions needed, but not derived
 directly from adverse effects of this study and not covered by regular health insurance
 systems, these events will be also covered by the insurance policy of this study. This
 insurance policy will be maintained current for up to 4 months after the completion of the
 study. Responsible rheumatologists to inform volunteers on the study, to clarify doubts or
 answering questions are Dr. Verónica I. Aguirre at Hospital de Valdivia and Dr. Sonia M.
 Arriagada at Hospital de Osorno.
Inclusion Criteria:

 -  Patients, between 18 and 70 years of age.

 -  Clinical diagnosis of RA, based on typical history and clinical presentation of the
 patient according to the diagnostic criteria of the American College of Rheumatology
 (ACR), 1987.

 -  Active AR characterized by pain and increase in joint volume, in at least 1 joint,
 associated to VHS > 20 mm/h and/or PCR > 0,6 ng/ml.

 -  Ambulatory patient requiring treatment with anti-inflammatory drugs, whom is neither
 receiving non-steroidal anti-inflammatory drugs (NSAIDs) nor any other drugs, except
 Paracetamol, for at least 4 weeks previous to the beginning of the study.

 -  Also, patients with RA treated with Prednisone and/or Chloroquine and Methotrexate in
 stable doses for at least 6 weeks, with active arthritis, and willing to participate
 in the study.

 -  Willing to come to regular controls.

 -  Written consent signed by the patient, according to the criteria and text approved by
 the local Scientific Ethical Committee.

 Exclusion Criteria:

 -  Pregnant women, breast feeding, childbirth, potentially fertile and / or not following
 adequate contraceptive methods.

 -  Non degenerative joint diseases or other joint diseases that could interfere with the
 evaluation of RA (i.e. Gout, Pseudogout, Chondrocalcinosis, Psoriatic Arthritis,
 Infectious Arthritis, Reactive Arthritis or Spondylitic Arthritis).

 -  Severe disabling arthritis leaving the patient eligible for surgical intervention, or
 incapacitated and prostrated patients.

 -  Treatment with intra-joint injection with corticosteroids one month before treatment.

 -  Ongoing treatment with anticoagulants, hydantoins or lithium.

 -  Presence or history of digestive hemorrhage, peptic ulcer in the 6 previous months or
 hemorrhagic ulcer any time during the past, gall bladder stones or dysfunction.

 -  Hypersensitivity and / or intolerant to NSAIDs, including patients with bronchospam
 history induced by Aspirin.

 -  Evidence of renal, hepatic and severe hematopoietic diseases, and heart failure
 revealed by laboratory tests or other tests.

 -  History of using any other test drug, one month before to the beginning of this trial.

 -  Patients with tranquilizers, hypnotic or excess of alcohol, which can interfere with
 the perception of pain.

 -  Necessity of any other therapy for arthrosis, except Paracetamol used as a rescue drug
 during the period of study. Also exercise and/or physiotherapy, if ongoing, can
 continue without modification.

 -  Not willing to come for regular follow ups during the period of duration of the study.

 -  Non cooperative attitude.

 -  Any condition that in the opinion of the physician, does not justify the inclusion of
 the patient in the study.